| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 38.696 | 40.401 | 37.932 | 39.010 | 724.522 | 906.022 | 1.003.858 | 9.846 | 23.032 | - |
| Total Income - EUR | 38.696 | 40.401 | 37.932 | 39.010 | 727.984 | 912.998 | 1.008.773 | 19.854 | 32.327 | - |
| Total Expenses - EUR | 28.975 | 31.937 | 29.837 | 11.104 | 606.399 | 758.041 | 827.257 | 319.756 | 206.070 | - |
| Gross Profit/Loss - EUR | 9.721 | 8.464 | 8.095 | 27.906 | 121.585 | 154.956 | 181.516 | -299.902 | -173.743 | - |
| Net Profit/Loss - EUR | 8.560 | 7.207 | 6.957 | 26.736 | 114.337 | 147.255 | 171.995 | -299.902 | -173.743 | - |
| Employees | 1 | 0 | 0 | 0 | 4 | 9 | 3 | 1 | 1 | - |
Check the financial reports for the company - Synerga Pharmaceuticals S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 8.918 | 9.445 | 8.600 | 9.093 | 51.108 | 50.244 | 44.513 | 13.044 | 14.886 | - |
| Current Assets | 1.905 | 1.603 | 1.256 | 4.826 | 712.642 | 726.666 | 539.866 | 258.718 | 118.826 | - |
| Inventories | 0 | 0 | 0 | 0 | 76.085 | 312.794 | 68.884 | 32.220 | 17.031 | - |
| Receivables | 3.421 | 1.533 | 1.246 | 4.792 | 580.210 | 213.479 | 44.688 | 29.236 | 101.737 | - |
| Cash | -1.517 | 70 | 10 | 34 | 56.347 | 200.393 | 426.294 | 106.013 | 58 | - |
| Shareholders Funds | -38.872 | -31.269 | -23.783 | 3.562 | 117.893 | 206.829 | 227.152 | -72.045 | -245.569 | - |
| Social Capital | 45 | 45 | 44 | 215 | 274 | 269 | 263 | 264 | 263 | - |
| Debts | 49.781 | 42.403 | 33.723 | 10.358 | 645.856 | 570.081 | 357.226 | 345.310 | 379.331 | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Synerga Pharmaceuticals S.r.l.